Dr. Claudia Duranti was born in Florence, Italy, in 1988. She received a B.S. in Biological Sciences in 2010 and an M.S. in Biomedical Biology in 2013 from the University of Florence, Italy (magna cum laude). She gained a Ph.D. in Experimental and Clinical Oncology (University of Florence) in 2017, and since then has taken up a post as a post-doctoral fellow at the Department of Experimental and Clinical Medicine (University of Florence). In 2019, she was appointed to a two-year Associazione Italiana per la Ricerca sul Cancro (AIRC) fellowship to study the development and application of recombinant antibodies for cancer therapy. Her main interests focus on the development of new molecules targeting cancer-related ion channels and transporters, antibody dye conjugation and 3D culture establishment. She is the first name and co-author of several original publications and the co-inventor of a patent.
Prof. Annarosa Arcangeli was born in Pistoia, Italy, in 1956. She graduated in medicine and surgery in 1981, became a specialist in clinical and laboratory hematology in 1984, and became a researcher in experimental pathology in 1990. Since 2012, she has been an ordinary professor of general pathology at the Faculty of Medicine and Surgery of the University of Florence. She has extensive experience in research on ion channels and their role in neoplastic transformation. She is among the world’s experts in hERG and its role in cancer. Through several periods of work at the University of Cambridge, she also gained considerable biotechnology experience in the genetic manipulation of mammals to produce genetically modified animals and in the production of monoclonal antibodies through the use of recombinant proteins in E. coli and yeasts.
